New rules will force EU medtech notified bodies to up their game
This article was originally published in SRA
Executive Summary
The European Commission has adopted two measures that it says are aimed at strengthening the safety of medical devices and restoring consumer confidence in the industry following the PIP breast implant affair1. The measures clarify the criteria to be met by notified bodies and the tasks these bodies have to undertake when they perform audits and assessments in the medical devices and in vitro diagnostics sector.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.